TXN Q2 Beat Confirms Broad Recovery; Free Cash Flow Inflects as Capex Cycle Ends

What happened

Texas Instruments' Q2 2026 results decisively cleared the hurdles that had kept the stock on a WAIT rating: revenue rose 23% YoY (well above the $5.0B-$5.4B guidance), operating profit jumped 48%, and net income climbed 53%, confirming that the Q1 industrial rebound was not a restock false start. Management's commentary continued to cite industrial and data center as growth leaders, while inventory days tightened further from Q1's 209. The headline event, however, is the end of the six-year elevated capex cycle: capital expenditures fell nearly 50% YoY, driving free cash flow up 56% and positioning TXN as a cash-flow machine with TTM FCF now exceeding $6.5B. This print validates the bull scenario laid out in the prior analysis, where capex normalization and improved utilization would expand cash conversion. The stock's reaction remains to be seen, but at $269.5 the market will likely reprice the recovery durability and the structural cash-flow improvement.

Implication

Investors should upgrade TXN from WAIT to BUY on this confirmation, as the Q2 beat removes the primary near-term risk. The capex downshift directly supports a re-rating toward the bull scenario's $310 implied value, contingent on sustained industrial breadth and no trade-policy shocks. However, at 45x earnings, much of the recovery is already priced, so entry points below $250 or on macro-induced pullbacks offer better risk-reward. Monitoring should focus on whether data center growth remains outsized (>60% YoY) and whether inventory days fall below 180 by Q4, as further tightening would reinforce pricing power. Conversely, any sign of industrial order air pockets or accelerated tariff implementation on China shipments would cap gains and justify trimming into strength.

Thesis delta

The previous WAIT rating was explicitly contingent on Q2 execution against $5.0B-$5.4B revenue guidance and continued inventory tightening; the reported 23% YoY revenue growth and sharp FCF increase clear both bars and signal the recovery is broad-based, not a head fake. This shifts the thesis to a BUY with increased conviction, as the structural cash-flow inflection from capex normalization adds a second independent driver beyond the cyclical rebound. The main residual risk is valuation, with the stock already trading at a premium multiple, but the improved fundamental trajectory justifies holding for the medium term.